Huntington disease stories

Sep 29, 2026

UniQure's Huntington's gene therapy shows weaker benefit after four years

UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.

Sep 29, 20263 sources

Sep 2, 2026

UniQure seeks FDA approval for Huntington's gene therapy after reversal

Dutch biotech UniQure submitted its Huntington's disease gene therapy to the FDA for approval after the agency reversed its earlier position on the experimental treatment, following an unusually turbulent development process.

Sep 2, 20263 sources

May 4, 2026

Latus Bio Raises $42 Million to Advance Huntington's Disease Gene Therapy Trial

Latus Bio secured $42 million in funding as it prepares to seek FDA approval to begin a clinical trial for its gene therapy targeting Huntington's disease, a progressive neurodegenerative disorder.

May 4, 20261 source